Determination of scattered radiation dose for radiological staff during portable chest examinations of COVID-19 patients.

The COVID-19 pandemic has resulted in a large increase in the number of patients admitted to hospitals. Radiological technologists (RTs) are often required to perform portable chest X-ray radiography on these patients. Normally, when performing a portable X-ray, radiation protection equipment is critical as it reduces the scatter radiation dose to hospital workers. However, during the pandemic, the use of a lead shield caused a heavy weight burden on workers who were responsible for a large number of patients. This study aimed to investigate scatter radiation doses received at various distances, directions, and positions. Radiation measurements were performed using the PBU-60 whole body phantom to determine scatter radiation doses at 100-200 cm and eight different angles around the phantom. The tests were conducted with and without lead shielding. Additionally, the doses were compared using the paired t test (p < 0.005) to determine suitable positions for workers who did not wear lead protection that adhered to radiation safety requirements. Scatter radiation doses of all 40 tests showed a highest and lowest value of 1285.5 nGy at 100 cm in the anteroposterior (AP) semi upright position and 134.7 nGy at 200 cm in the prone position, respectively. Correlation analysis between the dosimeter measurement and calculated inverse square law showed good correlation, with an R2 value of 0.99. Without lead shielding, RTs must stay at a distance greater than 200 cm from patients for both vertical and horizontal beams to minimize scatter exposure. This would allow for an alternative way of performing portable chest radiography for COVID-19 patients without requiring lead shielding.

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Adenovirus vectors offer a platform technology for vaccine development. The value of the platform has been proven during the COVID-19 pandemic. Although good stability at 2-8 °C is an advantage of the platform, non-cold-chain distribution would have substantial advantages, in particular in low-income countries. We have previously reported a novel, potentially less expensive thermostabilisation approach using a combination of simple sugars and glass micro-fibrous matrix, achieving excellent recovery of adenovirus-vectored vaccines after storage at temperatures as high as 45 °C. This matrix is, however, prone to fragmentation and so not suitable for clinical translation. Here, we report an investigation of alternative fibrous matrices which might be suitable for clinical use. A number of commercially-available matrices permitted good protein recovery, quality of sugar glass and moisture content of the dried product but did not achieve the thermostabilisation performance of the original glass fibre matrix. We therefore further investigated physical and chemical characteristics of the glass fibre matrix and its components, finding that the polyvinyl alcohol present in the glass fibre matrix assists vaccine stability. This finding enabled us to identify a potentially biocompatible matrix with encouraging performance. We discuss remaining challenges for transfer of the technology into clinical use, including reliability of process performance.